Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
C Gridelli, F De Marinis, M Di Maio, D Cortinovis… - Lung Cancer, 2011 - Elsevier
Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non–small-cell lung cancer: a meta-analysis of 13 randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical lung cancer, 2012 - Elsevier
Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
Non–small cell lung cancer
Most patients with non–small cell lung cancer (NSCLC) are diagnosed with advanced
cancer. These guidelines only include information about stage IV NSCLC. Patients with …
cancer. These guidelines only include information about stage IV NSCLC. Patients with …
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma …
PA Jänne, X Wang, MA Socinski, J Crawford… - Journal of clinical …, 2012 - ascopubs.org
Purpose Erlotinib is clinically effective in patients with non–small-cell lung cancer (NSCLC)
who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant …
who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant …
[HTML][HTML] Treatment of advanced non small cell lung cancer
MA Bareschino, C Schettino, A Rossi… - Journal of thoracic …, 2011 - ncbi.nlm.nih.gov
Lung cancer is the major cause of cancer death in the world. Non Small Cell Lung Cancer
(NSCLC) accounts approximately 80-85% of all lung cancer diagnosis; the majority of …
(NSCLC) accounts approximately 80-85% of all lung cancer diagnosis; the majority of …
EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects
Non-small cell lung cancer (NSCLC) tumours with certain mutations in the epidermal growth
factor receptor (EGFR) tyrosine kinase have been termed 'oncogene addicted'to reflect their …
factor receptor (EGFR) tyrosine kinase have been termed 'oncogene addicted'to reflect their …
[HTML][HTML] Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study
M Reck, N van Zandwijk, C Gridelli, Z Baliko… - Journal of Thoracic …, 2010 - Elsevier
Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
N Girard, CS Sima, DM Jackman… - European …, 2012 - Eur Respiratory Soc
Epidermal growth factor receptor (EGFR) tumour genotyping is crucial to guide treatment
decisions regarding the use of EGFR tyrosine kinase inhibitors in nonsmall cell lung cancer …
decisions regarding the use of EGFR tyrosine kinase inhibitors in nonsmall cell lung cancer …
[HTML][HTML] Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line …
E Bria, M Milella, F Cuppone, S Novello, A Ceribelli… - Annals of oncology, 2011 - Elsevier
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …
Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non–small-cell lung cancer
Worldwide, the majority of patients with advanced non–small-cell lung cancer (NSCLC) do
not have activating mutations in the tyrosine kinase domain of the epidermal growth factor …
not have activating mutations in the tyrosine kinase domain of the epidermal growth factor …